UniProt Q9UNZ5
Leydig cell tumor 10 kDa protein homolog (Q9UNZ5)
Leydig cell tumor 10 kDa protein homolog (UniProt Q9UNZ5): 7 experimental structures and 1 predicted model on GenesisL1. Binding sites, druggability and experiment against prediction (TM-score) in GL1X.
- UniProt
- Q9UNZ5
- Protein
- Leydig cell tumor 10 kDa protein homolog
- Experimental structures
- 7
- Predicted models
- 1
Structures
8 records of Q9UNZ5 in the MolNFT archive: 7 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 8FLA | Human nuclear pre-60S ribosomal subunit (State K1) | electron microscopy | VB | — | — |
| 8FLB | Human nuclear pre-60S ribosomal subunit (State K2) | electron microscopy | VB | — | — |
| 8FLC | Human nuclear pre-60S ribosomal subunit (State K3) | electron microscopy | VB | — | — |
| 8IDT | human nuclear pre-60S ribosomal particle - State G | electron microscopy | T | — | — |
| 8IDY | human nuclear pre-60S ribosomal particle - State F | electron microscopy | T | — | — |
| 8INE | human nuclear pre-60S ribosomal particle - State G' | electron microscopy | T | — | — |
| 8INF | human nuclear pre-60S ribosomal particle - State F' | electron microscopy | T | — | — |
| Q9UNZ5 | AlphaFold monomer V2.0 prediction for leydig cell tumor 10 kda protein homolog (Q9UNZ5) | predicted | A | — | — |
Experiment against prediction
- 8IDY chain T against the predicted model Q9UNZ5: TM-score 0.58, RMSD 2.16 Å
- 8IDT chain T against the predicted model Q9UNZ5: TM-score 0.56, RMSD 2.36 Å
- 8INF chain T against the predicted model Q9UNZ5: TM-score 0.56, RMSD 2.48 Å
- 8INE chain T against the predicted model Q9UNZ5: TM-score 0.54, RMSD 3.57 Å
- 8FLA chain VB against the predicted model Q9UNZ5: TM-score 0.52, RMSD 2.63 Å
- 8FLB chain VB against the predicted model Q9UNZ5: TM-score 0.52, RMSD 2.58 Å
- 8FLC chain VB against the predicted model Q9UNZ5: TM-score 0.51, RMSD 2.66 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.